mProX™ Human SDC1 Stable Cell Line

Product Information

Target Family

Other Targets

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;HepG2

Target Classification

Other Targets Drug Discovery Assays and Products

Target Research Area

Cancer Research

Related Diseases

Monoclonal Gammopathy Of Uncertain Significance; Endometritis

Gene ID

Human:6382

UniProt ID

Human:P18827

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

SDC1, or syndecan-1, plays a role in various biological processes and has been implicated in different medical conditions. In a study on acute lung injury (ALI), the administration of 1,1-dimethyl-4-phenylpiperazinium iodide (DMPP) was found to improve lung injury by inhibiting glycocalyx degradation through the activation of the cholinergic anti-inflammatory pathway. Another study focused on geriatric trauma patients and found that decreased glycocalyx shedding, as indicated by lower levels of syndecan-1, was associated with worse outcomes. In papillary thyroid carcinoma, an integrative analysis identified specific circRNAs, miRNAs, and hub genes, including SDC1, that play significant roles in tumor progression. Additionally, in Trichinella spiralis infection, the binding of T. spiralis C-type lectin to SDC-1 on intestinal epithelial cells mediated larval invasion of the intestinal epithelium. Finally, in the context of the SARS-CoV-2 Omicron variant, SDCs were found to be involved in the cellular internalization of the virus, with SDC4 having the most prominent effect on Omicron internalization. These studies highlight the diverse applications of SDC1 in different biological and pathological processes.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human SDC1 Stable Cell Line (S01YF-1023-PY287). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Alex Jones (Verified Customer)

What role does SDC1 play in glioblastoma radioresistance? Jun 27 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

SDC1, along with TGM2, is involved in the fusion of autophagosomes with lysosomes, a process that determines radiosensitivity in glioblastoma, offering insights into potential therapeutic targets for radioresistant GBM. Jun 27 2021

chat Skyler Garcia (Verified Customer)

How does SDC1 affect macrophage polarization in fibrosis? Jul 23 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

SDC1 influences macrophage polarization, as evidenced by its role in promoting an M1 to M2 macrophage transition in fibrosis, which could have implications for treating conditions like sciatic nerve injury. Jul 23 2022

Published Data

Fig.1 Knocking down of SDC1 in HepG2 CR cells.

A Western blotting assay was performed to assess the levels of SDC1 in HepG2 CR cells, with sh-ctrl or sh-SDC1 being stably expressed. Loading controls were provided by β-actin.

Ref: Yu, Liquan, et al. "SDC1 promotes cisplatin resistance in hepatic carcinoma cells via PI3K-AKT pathway." Human cell 33 (2020): 721-729.

Pubmed: 32314115

DOI: 10.1007/s13577-020-00362-6

Research Highlights

Qi, Feng. et al. "DMPP attenuates lipopolysaccharide-induced lung injury by inhibiting glycocalyx degradation through activation of the cholinergic anti-inflammatory pathway." Journal of bioenergetics and biomembranes, 2023.
The aim of this study was to investigate the therapeutic potential of 1,1-dimethyl-4-phenylpiperazinium iodide (DMPP), an agonist of nicotinic acetylcholine receptor (nAChR), in treating acute lung injury (ALI) induced by lipopolysaccharide (LPS). A murine ALI model was utilized to evaluate the therapeutic efficacy of DMPP treatment through various approaches, including pathohistological evaluation, appraisal of pulmonary edema, and measurement of inflammatory cytokine levels. Gene chip data retrieved from the Gene Expression Omnibus (GEO) database was also analyzed to assess the impact of DMPP on glycocalyx shedding. The results showed that DMPP treatment effectively improved pathomorphological changes and pathological lung injury scores in the LPS-induced ALI mouse model. Furthermore, gene differential expression and enrichment analyses revealed that DMPP treatment downregulated pro-inflammatory cytokines and suppressed important signaling pathways involved in LPS-induced ALI. The study also showed that DMPP treatment effectively restrained the upregulation of matrix metalloproteinase-9 and shedding of syndecan-1, contributing to the preservation of endothelial glycocalyx and attenuation of endothelial barrier dysfunction. These findings suggest that the administration of DMPP may confer protection against LPS-induced acute lung injury through a cholinergic anti-inflammatory pathway.
Qi, Feng. et al. "DMPP attenuates lipopolysaccharide-induced lung injury by inhibiting glycocalyx degradation through activation of the cholinergic anti-inflammatory pathway." Journal of bioenergetics and biomembranes, 2023.
Pubmed: 37851169 DOI: 10.1007/s10863-023-09989-0

Anand, Tanya. et al. "Decreased Glycocalyx Shedding on Presentation in Hemorrhaging Geriatric Trauma Patients." The Journal of surgical research, 2023.
The plasma levels of syndecan-1 (Sdc-1), a biomarker for endothelial glycocalyx (EG) damage, are known to be associated with worse outcomes in trauma patients. However, the extent of EG injury in older adults (OA) who have sustained trauma is not well understood. This study aimed to analyze Sdc-1 shedding in OA trauma patients compared to younger adults (YA) and investigate potential contributors to EG sheddase activity. Results may provide valuable insights into EG damage and potential interventions for improving outcomes in OA trauma patients.
Anand, Tanya. et al. "Decreased Glycocalyx Shedding on Presentation in Hemorrhaging Geriatric Trauma Patients." The Journal of surgical research, 2023.
Pubmed: 37844411 DOI: 10.1016/j.jss.2023.09.047